methyl 2-(3-nitrophenyl)propanoate | 138564-24-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 2-(3-nitrophenyl)propanoate
• 英文别名: methyl 2-(3-nitrophenyl)propionate；(+/-)-2-(3-nitro-phenyl)-propionic acid methyl ester；(+/-)-2-(3-Nitro-phenyl)-propionsaeure-methylester；methyl (RS)-2-(3-nitrophenyl)propionate
• CAS: 138564-24-6
• 化学式: C₁₀H₁₁NO₄
• mdl: MFCD23096910
• 分子量: 209.202
• InChiKey: VKHVGMRGUCBLLC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 2-(3-nitrophenyl)propanoate 在 1,4-二氧六环 、 甲醇 、 ammonium hydroxide 、 铂 作用下， 生成 (+/-)-2-(3-amino-phenyl)-propionic acid amide
  参考文献：
  名称：

  99mTc-sestamibi muscle scintigraphy to assess the response to neuromuscular electrical stimulation of normal quadriceps femoris muscle

  摘要：

  Objectives: Neuromuscular electrical stimulation (NMES) is widely used for improving muscle strength by simultaneous contraction in the prevention of muscle atrophy. Although there exist many clinical methods for evaluating the therapeutic response of muscles, Tc-99m-sestamibi which is a skeletal muscle perfusion and metabolism agent has not previously been used for this purpose. The aim of our work was to ascertain whether Tc-99m-sestamibi muscle scintigraphy is useful in the monitoring of therapeutic response to NMES in healthy women.Methods: The study included 16 women aged between 21 and 45, with a mean age of 32.7 +/- 6.4. Both quadriceps femoris muscles (QFM) of each patient were studied. After randomization to remove the effect of the dominant side, one QFM of each patient was subjected to the NMES procedure for a period of 20 days. NMES was performed with an alternating biphasic rectangular current, from a computed electrical stimulator daily for 23 minutes. After measurement of skinfold thickness over the thigh, pre- and post-NMES girth measurements were assessed in centimeters. Sixty minutes after injections of 555 MBq Tc-99m-sestamibi, static images of the thigh were obtained for 5 minutes. The thigh-to-knee uptake ratio was calculated by semiquantitative analysis and normalized to body surface area (NUR = normalized uptake ratio).Results: The difference between the pre and post NMES NUR values was Significant (1.76 +/- 0.31 versus 2.25 +/- 0.38, p = 0.0000). The percentage (%) increase in NUR values also well correlated with the % increase in thigh girth measurements (r = 0.89, p = 0.0000).Conclusion: These results indicated that Tc-99m-sestamibi muscle scintigraphy as a new tool may be useful in evaluating therapeutic response to NMES.

  DOI：

  10.1007/bf02988252
• 作为产物：
  描述：

  碘甲烷 在 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 以30%的产率得到methyl 2-(3-nitrophenyl)propanoate
  参考文献：
  名称：

  [EN] QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS
  [FR] DERIVES DE QUINOLINE ET DE QUINAZOLINE PRESENTANT UNE AFFINITE VIS-A-VIS DES RECEPTEURS DU TYPE 5HT1

  摘要：

  提供了式(I)的化合物及其药用盐：其中R1、m、X、R2、n、W、p、Y、Z、R3、R4、R5和q的含义如描述中所定义。还公开了制备方法以及在治疗中的用途，特别是用于抑郁症或焦虑等中枢神经系统疾病。

  公开号：

  WO2005014552A1

文献信息

• Stereoselective Ketone Rearrangements with Hypervalent Iodine Reagents
  作者：Florence Malmedy、Thomas Wirth

  DOI：10.1002/chem.201603022

  日期：2016.11.2

  The first stereoselective version of an iodine(III)‐mediated rearrangement of arylketones in the presence of orthoesters is described. The reaction products, α‐arylated esters, are very useful intermediates in the synthesis of bioactive compounds such as ibuprofen. With chiral lactic acid‐based iodine(III) reagents product selectivities of up to 73 % ee have been achieved.

  描述了在原酸酯存在下碘（III）介导的芳基酮重排的第一个立体选择性形式。反应产物α-芳基化酯是生物活性化合物（如布洛芬）合成中非常有用的中间体。使用基于手性乳酸的碘（III）试剂，产品选择性高达73％  ee。
• Palladium-Catalyzed α-Arylation of Carboxylic Acids and Secondary Amides via a Traceless Protecting Strategy
  作者：Zhi-Tao He、John F. Hartwig

  DOI：10.1021/jacs.9b03291

  日期：2019.7.31

  for the long-standing challenge of conducting the palladium-catalyzed α-arylation of carboxylic aids and secondary amides with aryl halides. Both of the presented coupling processes occur with a variety of carboxylic acids and amides and with a variety of aryl bromides containing a broad range of functional groups, including base-sensitive functionality like acyl, alkoxycarbonyl, nitro, cyano, and even

  针对钯催化羧酸助剂和仲酰胺与芳基卤化物的 α-芳基化这一长期存在的挑战，提出了一种新颖的无痕保护策略。所提出的两种偶联过程均与各种羧酸和酰胺以及各种含有多种官能团的芳基溴发生，包括碱敏感官能团，如酰基、烷氧基羰基、硝基、氰基，甚至羟基。通过该方法一步制备了5种商品化药物，收率81-96%。低钯负载量药物萘普生和氟比洛芬的克级合成进一步凸显了该方法的实用价值。
• Nonsteroidal antiinflammatory agents. 2. [(Heteroarylamino)phenyl]alkanoic acids
  作者：Katsuhiko Hino、Hideo Nakamura、Yasutaka Nagai、Hitoshi Uno、Haruki Nishimura

  DOI：10.1021/jm00356a019

  日期：1983.2

  A series of [(heteroarylamino)phenyl]alkanoic acids having pyridine, quinoline, or pyrimidine as the heteroaryl moiety was prepared as potential antiinflammatory agents. Among them, 2-[4-(2-pyridylamino)phenyl]propionic acid (14b) showed excellent antiinflammatory and analgesic activities with less tendency to cause gastric side effects. Structure-activity relationships are discussed.

  制备了具有吡啶，喹啉或嘧啶作为杂芳基部分的一系列[（杂芳基氨基）苯基]链烷酸作为潜在的抗炎剂。其中，2- [4-（2-吡啶基氨基）苯基]丙酸（14b）具有出色的抗炎和镇痛活性，较少引起胃副反应。讨论了构效关系。
• Integrin expression inhibitor
  申请人：Wakabayashi Toshiaki

  公开号：US20050176712A1

  公开（公告）日：2005-08-11

  The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them, wherein in the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, —CH═CH— or —(CR 4b R 5b ) m b — (wherein R 4b and R 5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and m b means an integer of 1 or 2); R 1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or —CO—NH—; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.

  本发明提供了一种整合素表达抑制剂，并提供了一种基于整合素抑制作用的用于治疗动脉硬化、银屑病、癌症、视网膜血管生成、糖尿病视网膜病变或炎症性疾病的药剂、抗凝剂或癌症转移抑制剂。换句话说，本发明提供了一种整合素表达抑制剂，其包括以下式（I）所表示的磺酰胺化合物作为活性成分、其药学上可接受的盐或其水合物： 其中，在上述式中，B表示C6-C10芳基环或6-至10元杂环芳基环，其中可能有取代基，并且环的一部分可能是饱和的；K表示单键，-CH═CH-或-(CR4bR5b)mb-（其中R4b和R5b相同或不同，每个表示氢原子或C1-C4烷基；mb表示1或2的整数）；R1表示氢原子或C1-C6烷基；Z表示单键或-CO-NH-；R分别表示C6-C10芳基环或6-至10元杂环芳基环，其中可能有取代基，并且环的一部分可能是饱和的。
• Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
  申请人：Bergauer Markus

  公开号：US20060229312A1

  公开（公告）日：2006-10-12

  Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided: wherein R 1 , m, X, R 2 , n, W, p, Y, Z, R 3 , R 4 , R 5 and q have the meanings as defined in the description. Methods of preparation and uses thereof in therapy, particularly for CNS disorders such as depression or anxiety, are also disclosed.

  提供式(I)的化合物和药学上可接受的盐：其中R1，m，X，R2，n，W，p，Y，Z，R3，R4，R5和q的含义如描述中所定义。还公开了制备方法以及在治疗中的用途，特别是用于中枢神经系统疾病，如抑郁症或焦虑症。